KalVista Pharmaceuticals

creating a new generation of small molecule protease inhibitors for HAE and DME

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824